Table Info

Table 3.

Targets of succinylation in the nucleus

Protein	Sites	Protein	Model	Reference
H2A	K9, K36, K95	-	In vitro study	[112]
H2B	K34	Destabilised nucleosome	In vitro study and budding yeast	[113]
H2B	K5, K43, K46, K85, K108, K116, K120	-	Review	[114]
H3	K122	Destabilised nucleosome Active transcription	Breast cancer cells	[115]
		Active transcription	Human pancreatic cancer cells	[27]
		Active hepatitis B virus (HBV) transcription	HBV-infected human liver	[41]
		Active hepatitis B virus (HBV) transcription	HBV-infected human hepatocytes	[116]
	K79	Active transcription	Human glioblastoma cells	[29]
		Active transcription β-catenin stabilization	Pancreatic cancer cells	[117]
		Active HBV transcription	Chimeric mice, HBV-infected human hepatocytes	[118]
	K9, K14, K23, K27, K56	-	In vitro study	[36, 112, 114]
H4	K77	DNA unwrapping Active transcription	In vitro study	[109]
H4	K12, K31, K79, K91	-	In vitro study	[111, 112]

-: no data

Declarations

Author contributions

KFK: Conceptualisation, Writing—original draft, Writing—review & editing, Supervision. DY and YG: Writing—original draft. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

YG was funded by a State Scholarship from the Chinese Scholarship Council [202208080293]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Liddy KA, White MY, Cordwell SJ. Functional decorations: post-translational modifications and heart disease delineated by targeted proteomics. Genome Med. 2013;5:20. [DOI] [PubMed] [PMC]

Khoury GA, Baliban RC, Floudas CA. Proteome-wide post-translational modification statistics: frequency analysis and curation of the swiss-prot database. Sci Rep. 2011;1:90. [DOI] [PubMed] [PMC]

Figlia G, Willnow P, Teleman AA. Metabolites regulate cell signaling and growth via covalent modification of proteins. Dev Cell. 2020;54:156–70. [DOI] [PubMed]

Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 1997;90:595–606. [DOI] [PubMed]

Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci U S A. 1964;51:786–94. [DOI] [PubMed] [PMC]

Smith KT, Workman JL. Introducing the acetylome. Nat Biotechnol. 2009;27:917–9. [DOI] [PubMed]

Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2019;574:575–80. [DOI] [PubMed] [PMC]

Peng C, Lu Z, Xie Z, Cheng Z, Chen Y, Tan M, et al. The first identification of lysine malonylation substrates and its regulatory enzyme. Mol Cell Proteomics. 2011;10:M111.012658. [DOI] [PubMed] [PMC]

Zhang Z, Tan M, Xie Z, Dai L, Chen Y, Zhao Y. Identification of lysine succinylation as a new post-translational modification. Nat Chem Biol. 2011;7:58–63. [DOI] [PubMed] [PMC]

10.

Tan M, Peng C, Anderson KA, Chhoy P, Xie Z, Dai L, et al. Lysine glutarylation is a protein posttranslational modification regulated by SIRT5. Cell Metab. 2014;19:605–17. [DOI] [PubMed] [PMC]

11.

Chen Y, Sprung R, Tang Y, Ball H, Sangras B, Kim SC, et al. Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteomics. 2007;6:812–9. [DOI] [PubMed] [PMC]

12.

Hofer A, Wenz T. Post-translational modification of mitochondria as a novel mode of regulation. Exp Gerontol. 2014;56:202–20. [DOI] [PubMed]

13.

Sabari BR, Zhang D, Allis CD, Zhao Y. Metabolic regulation of gene expression through histone acylations. Nat Rev Mol Cell Biol. 2017;18:90–101. [DOI] [PubMed] [PMC]

14.

Vadlakonda L, Dash A, Pasupuleti M, Anil Kumar K, Reddanna P. Did we get pasteur, warburg, and crabtree on a right note? Front Oncol. 2013;3:186. [DOI] [PubMed] [PMC]

15.

O’Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16:553–65. [DOI] [PubMed] [PMC]

16.

Culvenor JG, Weidemann MJ. Phytohaemagglutinin stimulation of rat thymus lymphocytes glycolysis. Biochim Biophys Acta. 1976;437:354–63. [DOI] [PubMed]

17.

Hedeskov CJ. Early effects of phytohaemagglutinin on glucose metabolism of normal human lymphocytes. Biochem J. 1968;110:373–80. [DOI] [PubMed] [PMC]

18.

Roos D, Loos JA. Changes in the carbohydrate metabolism of mitogenically stimulated human peripheral lymphocytes I. stimulation by phytohaemagglutinin. Biochim Biophys Acta. 1970;222:565–82. [DOI] [PubMed]

19.

Franchina DG, Grusdat M, Brenner D. B-cell metabolic remodeling and cancer. Trends Cancer. 2018;4:138–50. [DOI] [PubMed]

20.

Curi R, Levada-Pires AC, Silva EBD, Poma SO, Zambonatto RF, Domenech P, et al. The critical role of cell metabolism for essential neutrophil functions. Cell Physiol Biochem. 2020;54:629–47. [DOI] [PubMed]

21.

He W, Miao FJP, Lin DCH, Schwandner RT, Wang Z, Gao J, et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature. 2004;429:188–93. [DOI] [PubMed]

22.

de Castro Fonseca M, Aguiar CJ, da Rocha Franco JA, Gingold RN, Leite MF. GPR91: expanding the frontiers of Krebs cycle intermediates. Cell Commun Signal. 2016;14:3. [DOI] [PubMed] [PMC]

23.

Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, et al. Succinate is an inflammatory signal that induces IL-1β through HIF-α. Nature. 2013;496:238–42. [DOI] [PubMed] [PMC]

24.

Yang Y, Gibson GE. Succinylation links metabolism to protein functions. Neurochem Res. 2019;44:2346–59. [DOI] [PubMed] [PMC]

25.

Lu K, Han D. A review of the mechanism of succinylation in cancer. Medicine (Baltimore). 2022;101:e31493. [DOI] [PubMed] [PMC]

26.

Sun L, Zhang H, Gao P. Metabolic reprogramming and epigenetic modifications on the path to cancer. Protein Cell. 2022;13:877–919. [DOI] [PubMed] [PMC]

27.

Yang G, Yuan Y, Yuan H, Wang J, Yun H, Geng Y, et al. Histone acetyltransferase 1 is a succinyltransferase for histones and non‐histones and promotes tumorigenesis. EMBO Rep. 2021;22:e50967. [DOI] [PubMed] [PMC]

28.

Kurmi K, Hitosugi S, Wiese EK, Boakye-Agyeman F, Gonsalves WI, Lou Z, et al. Carnitine palmitoyltransferase 1A has a lysine succinyltransferase activity. Cell Rep. 2018;22:1365–73. [DOI] [PubMed] [PMC]

29.

Wang Y, Guo YR, Liu K, Yin Z, Liu R, Xia Y, et al. KAT2A coupled with the α-KGDH complex acts as a histone H3 succinyltransferase. Nature. 2017;552:273–7. [DOI] [PubMed] [PMC]

30.

Zorro Shahidian L, Haas M, Le Gras S, Nitsch S, Mourão A, Geerlof A, et al. Succinylation of H3K122 destabilizes nucleosomes and enhances transcription. EMBO Rep. 2021;22:e51009. [DOI] [PubMed] [PMC]

31.

Mills SE, Foster DW, McGarry JD. Interaction of malonyl-CoA and related-compounds with mitochondria from different rat tissues. Relationship between ligand binding and inhibition of carnitine palmitoyltransferase I. Biochem J. 1983;214:83–91. [DOI] [PubMed] [PMC]

32.

Huang F, Luo X, Ou Y, Gao Z, Tang Q, Chu Z, et al. Control of histone demethylation by nuclear-localized α-ketoglutarate dehydrogenase. Science. 2023;381:eadf8822. [DOI] [PubMed]

33.

Anmangandla A, Ren Y, Fu Q, Zhang S, Lin H. The acyl-CoA specificity of human lysine acetyltransferase KAT2A. Biochemistry. 2022;61:1874–82. [DOI] [PubMed] [PMC]

34.

Lu W, Che X, Qu X, Zheng C, Yang X, Bao B, et al. Succinylation regulators promote clear cell renal cell carcinoma by immune regulation and RNA N6-methyladenosine methylation. Front Cell Dev Biol. 2021;9:622198. [DOI] [PubMed] [PMC]

35.

Yokoyama A, Katsura S, Sugawara A. Biochemical analysis of histone succinylation. Biochem Res Int. 2017;2017:8529404. [DOI] [PubMed] [PMC]

36.

Liu J, Shangguan Y, Tang D, Dai Y. Histone succinylation and its function on the nucleosome. J Cell Mol Med. 2021;25:7101–9. [DOI] [PubMed] [PMC]

37.

Sreedhar A, Wiese EK, Hitosugi T. Enzymatic and metabolic regulation of lysine succinylation. Genes Dis. 2020;7:166–71. [DOI] [PubMed] [PMC]

38.

Hirschey MD. Old enzymes, new tricks: sirtuins are NAD(+)-dependent de-acylases. Cell Metab. 2011;14:718–9. [DOI] [PubMed] [PMC]

39.

Du J, Zhou Y, Su X, Yu JJ, Khan S, Jiang H, et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science. 2011;334:806–9. [DOI] [PubMed] [PMC]

40.

Park J, Chen Y, Tishkoff DX, Peng C, Tan M, Dai L, et al. SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways. Mol Cell. 2013;50:919–30. [DOI] [PubMed] [PMC]

41.

Yu HB, Cheng ST, Ren F, Chen Y, Shi XF, Wong VKW, et al. SIRT7 restricts HBV transcription and replication through catalyzing desuccinylation of histone H3 associated with cccDNA minichromosome. Clin Sci (Lond). 2021;135:1505–22. [DOI] [PubMed]

42.

Li L, Shi L, Yang S, Yan R, Zhang D, Yang J, et al. SIRT7 is a histone desuccinylase that functionally links to chromatin compaction and genome stability. Nat Commun. 2016;7:12235. [DOI] [PubMed] [PMC]

43.

Yuan H, Zhao M, Zhao L, Yun H, Yang G, Geng Y, et al. PRMT5 confers lipid metabolism reprogramming, tumour growth and metastasis depending on the SIRT7-mediated desuccinylation of PRMT5 K387 in tumours. Acta Pharmacol Sin. 2022;43:2373–85. [DOI] [PubMed] [PMC]

44.

Yu J, Sadhukhan S, Noriega LG, Moullan N, He B, Weiss RS, et al. Metabolic characterization of a Sirt5 deficient mouse model. Sci Rep. 2013;3:2806. [DOI] [PubMed] [PMC]

45.

Weinert BT, Scholz C, Wagner SA, Iesmantavicius V, Su D, Daniel JA, et al. Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep. 2013;4:842–51. [DOI] [PubMed]

46.

Wang J, Li L, Chai R, Zhang Z, Qiu H, Mao X, et al. Succinyl-proteome profiling of Pyricularia oryzae, a devastating phytopathogenic fungus that causes rice blast disease. Sci Rep. 2019;9:3409. [DOI] [PubMed] [PMC]

47.

Dong Y, Li P, Li P, Chen C. First comprehensive analysis of lysine succinylation in paper mulberry (Broussonetia papyrifera). BMC Genomics. 2021;22:225. [DOI] [PubMed] [PMC]

48.

Koronowski KB, Khoury N, Morris-Blanco KC, Stradecki-Cohan HM, Garrett TJ, Perez-Pinzon MA. Metabolomics based identification of SIRT5 and protein kinase C epsilon regulated pathways in brain. Front Neurosci. 2018;12:32. [DOI] [PubMed] [PMC]

49.

Rardin MJ, He W, Nishida Y, Newman JC, Carrico C, Danielson SR, et al. SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. Cell Metab. 2013;18:920–33. [DOI] [PubMed] [PMC]

50.

Sadhukhan S, Liu X, Ryu D, Nelson OD, Stupinski JA, Li Z, et al. Metabolomics-assisted proteomics identifies succinylation and SIRT5 as important regulators of cardiac function. Proc Natl Acad Sci U S A. 2016;113:4320–5. [DOI] [PubMed] [PMC]

51.

Carrico C, Meyer JG, He W, Gibson BW, Verdin E. The mitochondrial acylome emerges: proteomics, regulation by sirtuins, and metabolic and disease implications. Cell Metab. 2018;27:497–512. [DOI] [PubMed] [PMC]

52.

Villalba JM, Alcain FJ. Sirtuin activators and inhibitors. Biofactors. 2012;38:349–59. [DOI] [PubMed] [PMC]

53.

Wang Y, Liu Q, Huan Y, Li R, Li C, Sun S, et al. Sirtuin 5 overexpression attenuates glucolipotoxicity-induced pancreatic β cells apoptosis and dysfunction. Exp Cell Res. 2018;371:205–13. [DOI] [PubMed]

54.

Xiao ZP, Lv T, Hou PP, Manaenko A, Liu Y, Jin Y, et al. Sirtuin 5-mediated lysine desuccinylation protects mitochondrial metabolism following subarachnoid hemorrhage in mice. Stroke. 2021;52:4043–53. [DOI] [PubMed]

55.

Du Y, Hu H, Qu S, Wang J, Hua C, Zhang J, et al. SIRT5 deacylates metabolism-related proteins and attenuates hepatic steatosis in ob/ob mice. Ebiomedicine. 2018;36:347–57. [DOI] [PubMed] [PMC]

56.

Gut P, Matilainen S, Meyer JG, Pallijeff P, Richard J, Carroll CJ, et al. SUCLA2 mutations cause global protein succinylation contributing to the pathomechanism of a hereditary mitochondrial disease. Nat Commun. 2020;11:5927. [DOI] [PubMed] [PMC]

57.

Ou T, Yang W, Li W, Lu Y, Dong Z, Zhu H, et al. SIRT5 deficiency enhances the proliferative and therapeutic capacities of adipose-derived mesenchymal stem cells via metabolic switching. Clin Transl Med. 2020;10:e172. [DOI] [PubMed] [PMC]

58.

Wang GX, Meyer JG, Cai W, Softic S, Li ME, Verdin E, et al. Regulation of UCP1 and mitochondrial metabolism in brown adipose tissue by reversible succinylation. Mol Cell. 2019;74:844–57.e7. [DOI] [PubMed] [PMC]

59.

Hershberger KA, Abraham DM, Liu J, Locasale JW, Grimsrud PA, Hirschey MD. Ablation of Sirtuin5 in the postnatal mouse heart results in protein succinylation and normal survival in response to chronic pressure overload. J Biol Chem. 2018;293:10630–45. [DOI] [PubMed] [PMC]

60.

Zhang Y, Bharathi SS, Rardin MJ, Uppala R, Verdin E, Gibson BW, et al. SIRT3 and SIRT5 regulate the enzyme activity and cardiolipin binding of very long-chain acyl-CoA dehydrogenase. Plos One. 2015;10:e0122297. [DOI] [PubMed] [PMC]

61.

Ma Y, Qi Y, Wang L, Zheng Z, Zhang Y, Zheng J. SIRT5-mediated SDHA desuccinylation promotes clear cell renal cell carcinoma tumorigenesis. Free Radic Biol Med. 2019;134:458–67. [DOI] [PubMed]

62.

Abril YLN, Fernandez IR, Hong JY, Chiang YL, Kutateladze DA, Zhao Q, et al. Pharmacological and genetic perturbation establish SIRT5 as a promising target in breast cancer. Oncogene. 2021;40:1644–58. [DOI] [PubMed] [PMC]

63.

Tong Y, Guo D, Lin SH, Liang J, Yang D, Ma C, et al. SUCLA2-coupled regulation of GLS succinylation and activity counteracts oxidative stress in tumor cells. Mol Cell. 2021;81:2303–16.e8. [DOI] [PubMed]

64.

Greene KS, Lukey MJ, Wang X, Blank B, Druso JE, Lin MCJ, et al. SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis. Proc Natl Acad Sci U S A. 2019;116:26625–32. [DOI] [PubMed] [PMC]

65.

Yang X, Wang Z, Li X, Liu B, Liu M, Liu L, et al. SHMT2 desuccinylation by SIRT5 drives cancer cell proliferation. Cancer Res. 2018;78:372–86. [DOI] [PubMed]

66.

Liu X, Zhu C, Zha H, Tang J, Rong F, Chen X, et al. SIRT5 impairs aggregation and activation of the signaling adaptor MAVS through catalyzing lysine desuccinylation. EMBO J. 2020;39:e103285. [DOI] [PubMed] [PMC]

67.

Shuai L, Zhang LN, Li BH, Tang CL, Wu LY, Li J, et al. SIRT5 regulates brown adipocyte differentiation and browning of subcutaneous white adipose tissue. Diabetes. 2019;68:1449–61. [DOI] [PubMed]

68.

Johnson JM, Peterlin AD, Balderas E, Sustarsic EG, Maschek JA, Lang MJ, et al. Mitochondrial phosphatidylethanolamine modulates UCP1 to promote brown adipose thermogenesis. Sci Adv. 2023;9:eade7864. [DOI] [PubMed] [PMC]

69.

Hershberger KA, Abraham DM, Martin AS, Mao L, Liu J, Gu H, et al. Sirtuin 5 is required for mouse survival in response to cardiac pressure overload. J Biol Chem. 2017;292:19767–81. [DOI] [PubMed] [PMC]

70.

Meyer JG, Softic S, Basisty N, Rardin MJ, Verdin E, Gibson BW, et al. Temporal dynamics of liver mitochondrial protein acetylation and succinylation and metabolites due to high fat diet and/or excess glucose or fructose. PloS One. 2018;13:e0208973. [DOI] [PubMed] [PMC]

71.

Nakagawa T, Lomb DJ, Haigis MC, Guarente L. SIRT5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell. 2009;137:560–70. [DOI] [PubMed] [PMC]

72.

Hallows WC, Yu W, Smith BC, Devries MK, Ellinger JJ, Someya S, et al. Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction. Mol Cell. 2011;41:139–49. Erratum in: Mol Cell. 2011;41:493. [DOI] [PubMed] [PMC]

73.

Xiong Y, Guan KL. Mechanistic insights into the regulation of metabolic enzymes by acetylation. J Cell Biol. 2012;198:155–64. [DOI] [PubMed] [PMC]

74.

Goetzman ES, Bharathi SS, Zhang Y, Zhao XJ, Dobrowolski SF, Peasley K, et al. Impaired mitochondrial medium-chain fatty acid oxidation drives periportal macrovesicular steatosis in sirtuin-5 knockout mice. Sci Rep. 2020;10:18367. [DOI] [PubMed] [PMC]

75.

Martinez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun. 2020;11:102. [DOI] [PubMed] [PMC]

76.

Lagunas-Rangel FA. Role of SIRT5 in cancer. Friend or Foe? Biochimie. 2023;209:131–41. [DOI] [PubMed]

77.

Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, et al. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020;52:192–203. [DOI] [PubMed] [PMC]

78.

Jo SH, Son MK, Koh HJ, Lee SM, Song IH, Kim YO, et al. Control of mitochondrial redox balance and cellular defense against oxidative damage by mitochondrial NADP⁺-dependent isocitrate dehydrogenase*. J Biol Chem. 2001;276:16168–76. Erratum in: J Biol Chem. 2001;276:26732. [DOI] [PubMed]

79.

Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–44. [DOI] [PubMed] [PMC]

80.

Li F, He X, Ye D, Lin Y, Yu H, Yao C, et al. NADP(+)-IDH Mutations promote hypersuccinylation that impairs mitochondria respiration and iinduces apoptosis resistance. Mol Cell. 2015;60:661–75. [DOI] [PubMed]

81.

Alberghina L, Gaglio D. Redox control of glutamine utilization in cancer. Cell Death Dis. 2014;5:e1561. [DOI] [PubMed] [PMC]

82.

Xie M, Pei DS. Serine hydroxymethyltransferase 2: a novel target for human cancer therapy. Invest New Drugs. 2021;39:1671–81. [DOI] [PubMed]

83.

Lin ZF, Xu HB, Wang JY, Lin Q, Ruan Z, Liu FB, et al. SIRT5 desuccinylates and activates SOD1 to eliminate ROS. Biochem Biophys Res Commun. 2013;441:191–5. [DOI] [PubMed]

84.

Chen XF, Tian MX, Sun RQ, Zhang ML, Zhou LS, Jin L, et al. SIRT 5 inhibits peroxisomal ACOX 1 to prevent oxidative damage and is downregulated in liver cancer. EMBO reports. 2018;19:e45124. [DOI] [PubMed] [PMC]

85.

Qi H, Ning X, Yu C, Ji X, Jin Y, McNutt MA, et al. Succinylation-dependent mitochondrial translocation of PKM2 promotes cell survival in response to nutritional stress. Cell Death Dis. 2019;10:170. [DOI] [PubMed] [PMC]

86.

Wang F, Wang K, Xu W, Zhao S, Ye D, Wang Y, et al. SIRT5 desuccinylates and activates pyruvate kinase M2 to block macrophage IL-1β production and to prevent DSS-induced colitis in mice. Cell Rep. 2017;19:2331–44. [DOI] [PubMed]

87.

Ye X, Niu X, Gu L, Xu Y, Li Z, Yu Y, et al. Desuccinylation of pyruvate kinase M2 by SIRT5 contributes to antioxidant response and tumor growth. Oncotarget. 2017;8:6984–93. [DOI] [PubMed] [PMC]

88.

Wang YF, Zhao LN, Geng Y, Yuan HF, Hou CY, Zhang HH, et al. Aspirin modulates succinylation of PGAM1K99 to restrict the glycolysis through NF-κB/HAT1/PGAM1 signaling in liver cancer. Acta Pharmacol Sin. 2023;44:211–20. [DOI] [PubMed] [PMC]

89.

Kwon OK, Bang IH, Choi SY, Jeon JM, Na AY, Gao Y, et al. LDHA desuccinylase sirtuin 5 as a novel cancer metastatic stimulator in aggressive prostate cancer. Genomics Proteomics Bioinf. 2023;21:177–89. [DOI] [PubMed] [PMC]

90.

Li X, Zhang C, Zhao T, Su Z, Li M, Hu J, et al. Lysine-222 succinylation reduces lysosomal degradation of lactate dehydrogenase a and is increased in gastric cancer. J Exp Clin Cancer Res. 2020;39:172. [DOI] [PubMed] [PMC]

91.

Zhang X, Han J, Fan D, Wang J, Lin X, Zhang H, et al. Lysine-40 succinylation of TAGLN2 induces glioma angiogenesis and tumor growth through regulating TMSB4X. Cancer Gene Ther. 2023;30:172–81. [DOI] [PubMed]

92.

Wang X, Shi X, Lu H, Zhang C, Li X, Zhang T, et al. Succinylation inhibits the enzymatic hydrolysis of the extracellular matrix protein fibrillin 1 and promotes gastric cancer progression. Adv Sci (Weinh). 2022;9:e2200546. [DOI] [PubMed] [PMC]

93.

Wang C, Zhang C, Li X, Shen J, Xu Y, Shi H, et al. CPT1A‐mediated succinylation of S100A10 increases human gastric cancer invasion. J Cell Mol Med. 2019;23:293–305. [DOI] [PubMed] [PMC]

94.

Tretter L, Patocs A, Chinopoulos C. Succinate, an intermediate in metabolism, signal transduction, ROS, hypoxia, and tumorigenesis. Biochim Biophys Acta. 2016;1857:1086–101. [DOI] [PubMed]

95.

Sturtz LA, Diekert K, Jensen LT, Lill R, Culotta VC. A fraction of yeast Cu, Zn-superoxide dismutase and its metallochaperone, CCS, localize to the intermembrane space of mitochondria: a physiological role for SOD1 in guarding against mitochondrial oxidative damage. J Biol Chem. 2001;276:38084–9. [DOI] [PubMed]

96.

Nakajima Y, Miyahara I, Hirotsu K, Nishina Y, Shiga K, Setoyama C, et al. Crystallization and preliminary X-ray characterization of rat liver acyl-CoA oxidase. Acta Cryst. 2001;57:1680–1. [DOI] [PubMed]

97.

Capello M, Ferri-Borgogno S, Riganti C, Chattaragada MS, Principe M, Roux C, et al. Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest. Oncotarget. 2016;7:5598–612. [DOI] [PubMed] [PMC]

98.

Li N, Liu X. Phosphoglycerate mutase 1: its glycolytic and non-glycolytic roles in tumor malignant behaviors and potential therapeutic significance. Onco Targets Ther. 2020;13:1787–95. [DOI] [PubMed] [PMC]

99.

Wen CL, Huang K, Jiang LL, Lu XX, Dai YT, Shi MM, et al. An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2019;116:23264–73. [DOI] [PubMed] [PMC]

100.

Song Y, Zhong X, Gao P, Zhou C, Shi J, Wu Z, et al. Aspirin and its potential preventive role in cancer: an umbrella review. Front Endocrinol (Lausanne). 2020;11:3. [DOI] [PubMed] [PMC]

101.

Feng Y, Xiong Y, Qiao T, Li X, Jia L, Han Y. Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy. Cancer Med. 2018;7:6124–36. [DOI] [PubMed] [PMC]

102.

Kim HR, Park JS, Karabulut H, Yasmin F, Jun CD. Transgelin-2: a double-edged sword in immunity and cancer metastasis. Front Cell Dev Biol. 2021;9:606149. [DOI] [PubMed] [PMC]

103.

Handford PA. Fibrillin-1, a calcium binding protein of extracellular matrix. Biochim Biophys Acta. 2000;1498:84–90. [DOI] [PubMed]

104.

Kawagoe M, Tsuruga E, Oka K, Sawa Y, Ishikawa H. Matrix metalloproteinase-2 degrades fibrillin-1 and fibrillin-2 of oxytalan fibers in the human eye and periodontal ligaments in vitro. Acta Histochem Cytochem. 2013;46:153–9. [DOI] [PubMed] [PMC]

105.

Zhou X, Shi M, Cao J, Yuan T, Yu G, Chen Y, et al. S100 calcium binding protein A10, a novel oncogene, promotes the proliferation, invasion, and migration of hepatocellular carcinoma. Front Genet. 2021;12:695036. [DOI] [PubMed] [PMC]

106.

Chen H, Xu C, Jin Q, Liu Z. S100 protein family in human cancer. Am J Cancer Res. 2014;4:89–115. [PubMed] [PMC]

107.

Lou Y, Han M, Liu H, Niu Y, Liang Y, Guo J, et al. Essential roles of S100A10 in Toll-like receptor signaling and immunity to infection. Cell Mol Immunol. 2020;17:1053–62. [DOI] [PubMed] [PMC]

108.

Teratani T, Watanabe T, Kuwahara F, Kumagai H, Kobayashi S, Aoki U, et al. Induced transcriptional expression of calcium-binding protein S100A1 and S100A10 genes in human renal cell carcinoma. Cancer Lett. 2002;175:71–7. [DOI] [PubMed]

109.

Jing Y, Ding D, Tian G, Kwan KCJ, Liu Z, Ishibashi T, et al. Semisynthesis of site-specifically succinylated histone reveals that succinylation regulates nucleosome unwrapping rate and DNA accessibility. Nucleic Acids Res. 2020;48:9538–49. [DOI] [PubMed] [PMC]

110.

Hall MA, Shundrovsky A, Bai L, Fulbright RM, Lis JT, Wang MD. High-resolution dynamic mapping of histone-DNA interactions in a nucleosome. Nat Struct Mol Biol. 2009;16:124–9. [DOI] [PubMed] [PMC]

111.

Hang T, Chen W, Wu M, Zhan L, Wang C, Jia N, et al. Structural insights into the molecular mechanism underlying Sirt5-catalyzed desuccinylation of histone peptides. Biochem J. 2019;476:211–23. [DOI] [PubMed]

112.

Xie Z, Dai J, Dai L, Tan M, Cheng Z, Wu Y, et al. Lysine succinylation and lysine malonylation in histones. Mol Cell Proteomics. 2012;11:100–7. [DOI] [PubMed] [PMC]

113.

Jing Y, Liu Z, Tian G, Bao X, Ishibashi T, Li XD. Site-specific installation of succinyl lysine analog into histones reveals the effect of H2BK34 succinylation on nucleosome dynamics. Cell Chem Biol. 2018;25:166–74.e7. [DOI] [PubMed]

114.

Huang H, Sabari BR, Garcia BA, Allis CD, Zhao Y. SnapShot: histone modifications. Cell. 2014;159:458–e1. [DOI] [PubMed] [PMC]

115.

Shahidian LZ, Haas M, Le Gras S, Nitsch S, Mourao A, Geerlof A, et al. Succinylation of H3K122 destabilizes nucleosomes and enhances transcription. EMBO Rep. 2021;22:e51009. [DOI] [PubMed] [PMC]

116.

Yuan Y, Yuan H, Yang G, Yun H, Zhao M, Liu Z, et al. IFN-α confers epigenetic regulation of HBV cccDNA minichromosome by modulating GCN5-mediated succinylation of histone H3K79 to clear HBV cccDNA. Clin Epigenetics. 2020;12:135. [DOI] [PubMed] [PMC]

117.

Tong Y, Guo D, Yan D, Ma C, Shao F, Wang Y, et al. KAT2A succinyltransferase activity-mediated 14-3-3ζ upregulation promotes β-catenin stabilization-dependent glycolysis and proliferation of pancreatic carcinoma cells. Cancer Lett. 2020;469:1–10. [DOI] [PubMed]

118.

Qin YP, Yu HB, Yuan SY, Yang Z, Ren F, Wang Q, et al. KAT2A promotes hepatitis B virus transcription and replication through epigenetic regulation of cccDNA minichromosome. Front Microbiol. 2022;12:795388. [DOI] [PubMed] [PMC]

119.

Xia Y, Guo H. Hepatitis B virus cccDNA: formation, regulation and therapeutic potential. Antiviral Res. 2020;180:104824. [DOI] [PubMed] [PMC]

120.

Wei L, Ploss A. Mechanism of hepatitis B virus cccDNA formation. Viruses. 2021;13:1463. [DOI] [PubMed] [PMC]

121.

Liu J, Qian C, Cao X. Post-translational modification control of innate immunity. Immunity. 2016;45:15–30. [DOI] [PubMed]

122.

Palsson-McDermott EM, Curtis AM, Goel G, Lauterbach MAR, Sheedy FJ, Gleeson LE, et al. Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the Warburg effect in LPS-activated macrophages. Cell Metab. 2015;21:65–80. Erratum in: Cell Metab. 2015;21:347. [DOI] [PubMed] [PMC]

123.

Gao X, Wang H, Yang JJ, Liu X, Liu ZR. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell. 2012;45:598–609. [DOI] [PubMed] [PMC]

124.

Damasceno LEA, Prado DS, Veras FP, Fonseca MM, Toller-Kawahisa JE, Rosa MH, et al. PKM2 promotes Th17 cell differentiation and autoimmune inflammation by fine-tuning STAT3 activation. J Exp Med. 2020;217:e20190613. [DOI] [PubMed] [PMC]

125.

Lu Z, Hunter T. Metabolic kinases moonlighting as protein kinases. Trends Biochem Sci. 2018;43:301–10. [DOI] [PubMed] [PMC]

126.

Rehwinkel J, Gack MU. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol. 2020;20:537–51. [DOI] [PubMed] [PMC]

127.

Wu B, Hur S. How RIG-I like receptors activate MAVS. Curr Opin Virol. 2015;12:91–8. [DOI] [PubMed] [PMC]

128.

Heinonen T, Ciarlo E, Theroude C, Pelekanou A, Herderschee J, Le Roy D, et al. Sirtuin 5 deficiency does not compromise innate immune responses to bacterial infections. Front Immunol. 2018;9:2675. [DOI] [PubMed] [PMC]

129.

Liu Q, Wang H, Zhang H, Sui L, Li L, Xu W, et al. The global succinylation of SARS-CoV-2-infected host cells reveals drug targets. Proc Natl Acad Sci U S A. 2022;119:e2123065119. [DOI] [PubMed] [PMC]

130.

Buler M, Aatsinki SM, Izzi V, Uusimaa J, Hakkola J. SIRT5 is under the control of PGC-1α and AMPK and is involved in regulation of mitochondrial energy metabolism. FASEB J. 2014;28:3225–37. [DOI] [PubMed]

131.

Chouchani ET, Pell VR, Gaude E, Aksentijevic D, Sundier SY, Robb EL, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014;515:431–5. [DOI] [PubMed] [PMC]

132.

Pell VR, Chouchani ET, Frezza C, Murphy MP, Krieg T. Succinate metabolism: a new therapeutic target for myocardial reperfusion injury. Cardiovasc Res. 2016;111:134–41. [DOI] [PubMed]

133.

Mills EL, Kelly B, Logan A, Costa ASH, Varma M, Bryant CE, et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell. 2016;167:457–70.e13. [DOI] [PubMed] [PMC]

134.

Fiorentino F, Castiello C, Mai A, Rotili D. Therapeutic potential and activity modulation of the protein lysine deacylase sirtuin 5. J Med Chem. 2022;65:9580–606. [DOI] [PubMed] [PMC]

135.

Itoh Y. Drug discovery researches on modulators of lysine-modifying enzymes based on strategic chemistry approaches. Chem Pharm Bull (Tokyo). 2020;68:34–45. [DOI] [PubMed]

136.

Jiang S, Yan W. Succinate in the cancer-immune cycle. Cancer Lett. 2017;390:45–7. [DOI] [PubMed]